GSK Doubles Phase 3 Trial Starts as £1.9bn Cost Plan Funds Pipeline Push

References

1. 1.Joseph, A. (2026, July 28). GSK lays out plans to cut costs, pursue more late-stage drug trials. STAT News. https://www.statnews.com/2026/07/28/gsk-earnings-report-luke-miels-strategy-late-stage-clinical-trials/
2. 2.Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology, 32(1), 40–51. https://doi.org/10.1038/nbt.2786
3. 3.Philippidis, A. (2023). Best-in-class vs. first-in-class: Rethinking drug development strategy. Genetic Engineering & Biotechnology News. https://www.genengnews.com/topics/drug-discovery/best-in-class-vs-first-in-class-rethinking-drug-development-strategy/
4. 4.Chambers, J. D., Thorat, T., Pyo, J., Chenoweth, M., & Neumann, P. J. (2014). Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Affairs, 33(10), 1751–1760. https://doi.org/10.1377/hlthaff.2013.0557
5. 5.Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20(2), 273–286. https://doi.org/10.1093/biostatistics/kxx069
6. 6.National Health and Medical Research Council. (2023). Ethical conduct in research with Aboriginal and Torres Strait Islander Peoples and communities: Guidelines for researchers and stakeholders. NHMRC. https://www.nhmrc.gov.au/about-us/publications/ethical-conduct-research-aboriginal-and-torres-strait-islander-peoples-and-communities
7. 7.Scannell, J. W., & Bosley, J. (2016). When should you enter a new drug market? The timing of competitive entry and its effect on new drug development costs. PLOS ONE, 11(2), e0146360. https://doi.org/10.1371/journal.pone.0146360
8. 8.IQVIA Institute for Human Data Science. (2024). Global trends in R&D 2024: Activity, productivity, and enablers. IQVIA Institute. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024
9. 9.Australian Government Department of Health and Aged Care. (2024). Pharmaceutical Benefits Scheme: Horizon scanning and early access to medicines. Australian Government. https://www.health.gov.au/topics/drugs-and-controlled-substances/pharmaceutical-benefits-scheme